CORVUS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.92 USD | +10.98% |
|
+32.41% | +9.09% |
Presenter SpeechRichard Miller (Executives)I think we should get started. We have a lot to cov...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumorâs ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Companyâs third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
Calendar
2024-05-05
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.73
USD
Average target price
7.5
USD
Spread / Average Target
+333.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.09% | 84.84M | |
| +25.69% | 48.09B | |
| +46.90% | 40.62B | |
| -3.46% | 40.43B | |
| -6.20% | 28.36B | |
| +9.17% | 24.89B | |
| -20.42% | 19.01B | |
| +28.07% | 12.09B | |
| +0.17% | 11.88B | |
| -1.24% | 11.8B |
- Stock Market
- Equities
- CRVS Stock
- News Corvus Pharmaceuticals, Inc.
- Transcript : Corvus Pharmaceuticals, Inc. - Special Call
